Performance of CAST (Cellular Antigen Stimulation Test) in Patients With Wasp Venom Allergy: Evaluation of Neutralizing IgG Subclasses

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00794287
First received: November 19, 2008
Last updated: June 3, 2015
Last verified: June 2015
  Purpose

To determine which subclass of IgG in the serum of patients undergoing SIT against wasp venom is able to neutralize the allergen, and therefore to prevent a positive CAST


Condition Intervention
Wasp Venom Allergic Patients
Other: Taking blood samples

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Performance of CAST (Cellular Antigen Stiumulation Test)in Patients With Wasp Venom Allergy. Evaluation of Neutralizing IgG Subclasses

Further study details as provided by University of Zurich:

Biospecimen Retention:   Samples Without DNA

Blood samples


Enrollment: 0
Study Start Date: January 2009
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Hymenoptera allergic patients before allergen specific immunotherapy
Other: Taking blood samples
No intervention is done. Only blood samples are taken.
2
Hymenoptera allergic patients after allergen specific immunotherapy
Other: Taking blood samples
No intervention is done. Only blood samples are taken.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Wasp venom allergic patients grade III and IV according to H.L. Müller in the age group of 18-75 years

Criteria

Inclusion criteria:

  • male and female patient with allergy to wasp venom grade III and IV according to H.L. Müller
  • 18-75 years
  • planned SIT against wasp venom or finished 5 years SIT against wsp venom (10/10)

Exclusion criteria:

  • oral corticosteroids
  • chromogycin
  • ketotifen
  • immunosuppressive drugs within the last 2 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00794287

Locations
Switzerland
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: PD Dr. Thomas Kündig, University of Zurich
ClinicalTrials.gov Identifier: NCT00794287     History of Changes
Other Study ID Numbers: ZU-AgNT-004
Study First Received: November 19, 2008
Last Updated: June 3, 2015
Health Authority: Switzerland: UZurich

ClinicalTrials.gov processed this record on July 01, 2015